CAREDX INC (CDNA)
Health Care · Molecular Diagnostics · NASDAQ
CareDx is a precision medicine leader providing diagnostic testing, digital health tools, and patient support services to improve outcomes for transplant and oncology patients.
What CAREDX INC does
CareDx is a precision medicine company focused on the transplant, specialty oncology, and cell therapy markets. The company provides non-invasive molecular testing, clinical practice management software, AI-powered data and analytics tools, and patient support solutions to help clinicians manage patients and improve transplant outcomes. Its testing portfolio includes donor-derived cell-free DNA (dd-cfDNA) and gene expression profiling solutions for kidney, heart, and lung transplant patients, as well as blood-based tests for HPV-mediated cancers.
Themes: transplant diagnostics, precision medicine, cell-free DNA testing, digital health solutions, oncology diagnostics, genomics-based informatics
Fundamentals
- Price$62.21 as of 2026-10-08 close
- Market cap$3.2B as of 2026-07-27 (share count; price 2026-10-08)
- 1-year return+320.6% 2025-10-08 close $14.79 → 2026-10-08 close $62.21
- P/E29.98 as of 2026-10-08
- Net margin-5.6% FY2025, SEC XBRL
- ROE-7.0% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Revenue growth (YoY)+34.4% as of 2026-09-03
- Revenue CAGR (3y)+5.7% SEC XBRL
- Beta1.32 as of 2026-09-03
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How CDNA compares in its sector
- price-to-earnings ratiomiddle range 185 covered Health Care peers, as of 2026-10-08
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
CDNA is not currently in any published Top 10 list. Its scores are below.
Top 10 score
52.2 #617 of 1,379 scored · #75 of 151 in Health Care
Trend 89th (a strong uptrend, with buyers in control) and growth 67th (revenue growth year over year 34.4%, 3-year revenue CAGR 5.7%); weakest is profitability (10th, operating margin -8.1%, return on equity -7%).
Left this list on 1 Oct 2026
- Left 1 Oct 2026: score 53.1, rank 68 (not compared with 1 Sep 2026 — those rows were scored under method version 3, this pass under 4, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).
- Entered 1 Sep 2026: score 72.3, rank 4 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How CAREDX INC looks technically
CAREDX INC (CDNA) is trading 110.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 202 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 56, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative). It made a new 20-day high about 4 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 110.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +110.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $52.54 | $52.54 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $29.63 | $29.63 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 38 calendar days ago — the swings before that are what the structure reading is measured on | 38 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 46.6879. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 202 trading days ago — a "golden cross", a bullish long-term signal | 202 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 56, with buyers in control | 56.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30) | 59.0 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($53.50 to $72.51) — its "stochastic" reading is 46 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 45.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $72.51 | $72.51 |
|---|---|---|
| From the 52-week high | it is 14.2% below its 52-week high (its highest price of the past year) | -14.2% |
| Above the 52-week low | it is 345.9% above its 52-week low (its lowest price of the past year) | +345.9% |
| Below the 52-week high | it is 14.2% below its highest point of the past year | 14.2% |
| Since a 20-day breakout | it made a new 20-day high about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day high about 4 trading days ago | 4 sessions |
| All-time high | its highest closing price on record is $99.83 (set on 2021-01-20) | $99.83 |
| Given back of the 52-week move | over the past year its closes ranged ($14.28 to $69.85), and it has given back only a small part of its rise from last year’s low — 14% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $33.73 to $35.51. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 13.8% |
| From the all-time high | it is 37.7% below its all-time high | -37.7% |
| Nearest price level | it is trading 62.7% above a support level at $23.19 — a price it turned at twice since 2026-04-17, most recently on 2026-04-29. Since 2024-10-08 it has 12 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -62.7% |
| All-time low | its lowest closing price on record is $0.76 (set on 2017-04-28) | $0.76 |
| Above the all-time low | it is 8084.9% above its all-time low | +8,085% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 64th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $3.39 between its high and its low — about 5.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $3.39 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $47.93 and $71.37 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $47.93 – $59.65 – $71.37 |
| Typical daily range (% of price) | its price moves about 5.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.5% |
| Stretch from the 200-day average | it is trading 9.6 daily ranges above its 200-day average price (110.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 9.6 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.15× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 4.8% since the prior reading | +4.8% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.18 toward buy |
Candlestick patterns
2
| Since a bullish engulfing | 6 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 6 sessions ago |
|---|---|---|
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 2.6% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -2.6% |
|---|---|---|
| Open gap | it gapped 8.0% above the previous close 47 sessions ago and has not traded back through the level it left behind at 43.71 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +8.0% |
| Gap filled | a 2.6% gap down opened on 2026-10-08 has been "filled" today — price traded back through the level the gap left behind, and it closed again during the very session that opened it | today |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -10.94% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 22.6 percentage points (the stock gained 23.6% while the market gained 1.0%) | +22.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 122.0 percentage points (the stock gained 125.8% while the market gained 3.8%) | +122.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 231.6 percentage points (the stock gained 249.1% while the market gained 17.5%) | +231.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 305.6 percentage points (the stock gained 320.6% while the market gained 15.0%) | +305.6% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a strong uptrend, with buyers in control, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 33% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 13.1% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +32.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 78% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $34.90 — a volume-weighted average of daily closes over 191 sessions, not a true tick-by-tick VWAP. | +78.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 16% above the average price paid since it last reported on 2026-07-30 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $53.49 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | +16.3% |
Price levels it has turned at before
CDNA last closed at $62.20 on 2026-10-08. Since 2024-10-08 it has turned at 12 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $23.19 | Support | 62.7% below the last close | turned there twice · 2026-04-17 to 2026-04-29 |
| $21.41 | Support | 65.6% below the last close | turned there three times · 2025-02-07 to 2026-02-03 |
| $20.95 | Support | 66.3% below the last close | turned there six times · 2024-11-05 to 2026-02-11 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $46.69.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $55.56 and $61.04 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $46.69.
This reading has stood for 23 trading days, since 2026-09-08.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · MACD just crossed bearish (12/26/9) · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · beating the market · Stretched far above its 200-day average (6+ daily ranges) | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.57 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$58.83 range $46.00 – $74.00; median $61.00
Analyst estimates, as of 2026-10-07. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CDNA
- Consensus EPS estimate$0.255 next reporting period, as of 2026-10-07
- Estimate change, 30 days+$0.005 (+2.0%) from $0.25, on 2026-09-02, 35-day window
- Readings revised upward40% of 5 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on coverage policies and reimbursement from third-party insurers and government payers.","Requirement for significant ongoing investment in clinical studies to generate supporting data for tests.","Operating results may be volatile due to the complexity of collecting revenue from payers without established coverage."]
What changed in the latest 10-Q
AI-assisted comparison of CDNA's 10-Q filed 2026-07-30 against the prior one filed 2026-04-28.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing adds a specialty oncology service description: NavDx, a blood-based test for HPV-mediated cancers including head, neck, and anal cancers, with MRD surveillance.
- Newer filing adds a Highlights bullet for the three months ended June 30, 2026 with revenue of $132 million (52% increase year-over-year).
- Newer filing adds a Highlights bullet for Testing Services revenue of $100 million (61% increase year-over-year) and volume of approximately 58,000 (17% increase year-over-year).
- Newer filing adds a Highlights bullet for Patient and Digital Solutions revenue of $19 million and Lab Product revenue of $13 million (50% and 8% year-over-year growth, respectively).
- Newer filing adds a Highlights bullet for average revenue per test of approximately $1,720 including $16 million in prior period revenue.
- Newer filing adds a Highlights bullet for net income of $111 million compared to net loss of $9 million for the second quarter of 2025.
- Newer filing adds a Highlights bullet stating the sale of the Lab Products business was closed on June 30, recognizing a $113 million gain on sale included in operating income.
- Newer filing adds a Highlights bullet for cash flow from operations of $31 million.
- Newer filing adds a statement that the company completed the sale of its lab products business, including kitted laboratory products, to Eurobio on June 30, 2026, with a reference to Note 1 of the financial statements.
- Removed:
- Older filing includes an Overview statement that the company is dedicated to improving outcomes for transplant patients and advancing organ health.
- Older filing includes an Overview statement that the company is the leading provider of genomics-based information for transplant patients.
- Older filing includes an Overview statement describing pre-transplant products that increase the chance of successful transplants by facilitating better donor-recipient matching of stem cells and organs.
- Older filing includes Highlights for the three months ended March 31, 2026 (revenue of $118 million, testing services revenue of $91 million, volume of approximately 54,900, patient and digital solutions revenue of $16 million, lab product revenue of $10 million, average revenue per test of approximately $1,660 including approximately $14 million in prior period revenue, net income of $3 million, cash flow from operations of $4 million).
- Older filing includes a section heading 'Development of Additional Services and Products' paragraph describing the development pipeline and expected investment in research and development.
- Reworded:
- Overview description changed from 'focused on transplant patients and organ health' to 'dedicated to advancing care in transplant, specialty oncology, and cell therapy'.
- Overview portfolio description changed from listing laboratory products and digital health technologies to listing 'clinical practice management software, AI-powered data and analytics tools, and patient support solutions'.
- Testing Services Revenue percentage disclosure changed from '78% for the three months ended March 31, 2026 and 73% for the three months ended March 31, 2025' to '76% and 77% for the three and six months ended June 30, 2026, respectively, and 72% for each of the three and six months ended June 30, 2025'.
- Product Revenue percentage disclosure changed from '9% for the three months ended March 31, 2026 and 13% for the three months ended March 31, 2025' to '10% and 9% for the three and six months ended June 30, 2026, respectively, and 14% and 13% for the three and six months ended June 30, 2025, respectively'.
- Patient and Digital Solutions Revenue percentage disclosure changed from '14% for each of the three months ended March 31, 2026 and March 31, 2025' to '15% and 14% for the three and six months ended June 30, 2026, respectively, and 15% and 14% for the three and six months ended June 30, 2025, respectively'.
- Revenue section first sentence changed from 'We derive our revenue from testing services, products sales, patient and digital solutions revenues' to 'We derive our revenue from testing services, product sales, and patient and digital solutions'.
- Product Revenue paragraph in newer filing adds a sentence stating the company completed the sale of its lab products business to Eurobio on June 30, 2026.
- Notes:
- The older filing text appears truncated at the end mid-sentence ('Timing of Research and Development Expenses Our spending on research a'), so comparisons beyond that point are limited.
- Percentage and financial figures differ between filings because they cover different fiscal quarters (Q1 2026 vs Q2 2026) and corresponding comparative periods.
Risk Factors
- Added:
- In the newer filing (2026-07-30), Medicare revenue disclosure now states '37% of our testing services revenue and 30% of our total revenue' as of June 30, 2026.
- Removed:
- In the older filing (2026-04-28), the second paragraph under 'We receive a substantial portion of our revenues from Medicare...' ended with 'including: when there are signs or symptoms o'. In the newer filing (2026-07-30), the section continues with '...after a physician-' after 'including: when there are signs or symptoms'. This appears to be a text truncation difference rather than a substantive removal.
- Reworded:
- Risk factor heading changed from 'We have a history of losses, and we expect to incur net losses for the next several years.' (older, 2026-04-28) to 'We have a history of net losses, and we may not sustain profitability.' (newer, 2026-07-30).
- Financial metrics updated from the older filing (2026-04-28) to the newer filing (2026-07-30): three months ended March 31, 2026 net income of $2.8 million changed to three months ended June 30, 2026 net income of $110.6 million; three months ended March 31, 2025 net loss of $10.4 million changed to three months ended June 30, 2025 net loss of $8.6 million; accumulated deficit as of March 31, 2026 of $732.5 million changed to accumulated deficit as of June 30, 2026 of $505.4 million.
- Introductory sentence in the first risk factor changed from 'We have incurred substantial net losses since our inception, and we may continue to incur additional losses for the next several years.' (older, 2026-04-28) to 'We have a history of substantial net losses since our inception, and we may incur net losses in future periods.' (newer, 2026-07-30).
- In the first bullet point, 'potential new testing services, products and patient and digital solutions' (older, 2026-04-28) changed to 'potential new testing services and patient and digital solutions' (newer, 2026-07-30), removing 'products'.
- In the first bullet point, 'testing services and product portfolio' (older, 2026-04-28) changed to 'testing services and portfolio' (newer, 2026-07-30), removing 'product'.
- In the Medicare revenue paragraph, '35% of testing services revenue' (older, 2026-04-28) changed to '37% of our testing services revenue and 30% of our total revenue' (newer, 2026-07-30).
- Notes:
- The newer filing text ends abruptly mid-sentence at 'including: when there are signs or symptoms of rejection; after a physician-' and the older filing text also ends abruptly at 'including: when there are signs or symptoms o', so the comparison beyond that point could not be evaluated.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 9 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 9 sells ($9M) — 6 selling insiders
- Last 180 days · read to 2026-10-040 buys · 19 sells ($12M) — 7 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-05. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CDNA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding CDNA as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 10,975,539
- Reported value $312,802,860
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about CDNA's institutional holders → See what each manager we track holds →
Short interest (FINRA)
CDNA had 6,297,191 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
CDNA had 12.2% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.29 days to cover at the same settlement.
- Reported short interest (shares) 6,297,191
- Short interest (% of shares outstanding) 12.2%
- Prior settlement (shares) 5,828,536
- Reported change 8.04%
- Days to cover (reported) 6.29
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Natera (NTRA)
- Veracyte (VCYT)
- Exact Sciences (EXAS)
- Guardant Health (GH)
- Illumina (ILMN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CDNA vs…
CAREDX INC is found in…
CDNA ranks in…
Frequently asked questions
What does CAREDX INC (CDNA) do?
CareDx is a precision medicine company focused on the transplant, specialty oncology, and cell therapy markets. The company provides non-invasive molecular testing, clinical practice management software, AI-powered data and analytics tools, and patient support solutions to help clinicians manage patients and improve transplant outcomes.
What sector is CAREDX INC (CDNA) in?
CAREDX INC (CDNA) is classified in the Health Care sector. Its industry is Molecular Diagnostics. It trades on NASDAQ.
Who are CAREDX INC's (CDNA) competitors?
Notable peers of CAREDX INC (CDNA) include Natera, Veracyte, Exact Sciences, Guardant Health and Illumina. This peer set is informational only — not financial advice.
Is CAREDX INC (CDNA) overbought or oversold right now?
CAREDX INC (CDNA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 59, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CDNA come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.